ArticleInternational journal of urology : official journal of the Japanese Urological Association2025
Utility of Combining Prostate Health Index and Magnetic Resonance Imaging for the Diagnosis of Prostate Cancer.
Article in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- Article
- The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate-Specific Antigen Levels Below 10 Ng/mL.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.International journal of urology : official journal of the Japanese Urological Association · 2026Review
- Integrated Assessment of Percentage α2,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer.European urology open science · 2026Article
- Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025Review
- The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.The Prostate · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this study, we compared the prostate health index (PHI) and the Prostate Imaging Reporting and Data System (PI-RADS) before prostate biopsy and evaluated the utility of combining them in the diagnosis of prostate cancer (PC).
methodsBetween November 2021 and March 2023, 105 patients admitted to Gunma University Hospital for prostate biopsy after undergoing both MRI and PHI measurements were enrolled in this study. We investigated the diagnostic impacts of [-2]proPSA related indexes on clinically significant PC (csPC) and the complementary effects of PHI and PI-RADS.
resultsThe median of PHI was 59.9, and 72 patients (69%) were diagnosed with PC. The receiver operating characteristic (ROC) curve for patients diagnosed with PC indicated an area under the curve (AUC) of 0.816 for PHI and 0.753 for PI-RADS. For PHI, when the sensitivity was 90% and 95%, the specificity was 51.5% and 45.5%, respectively. Both are higher than those of the conventional PSA-related indices. In addition, the ROC curve in patients with a diagnosis of csPC (n = 67) indicated an AUC of 0.793 for PHI and 0.746 for PI-RADS. Furthermore, if biopsy was restricted to patients with PI-RADS ≥ 4 or PHI ≥ 38.1, 21% of unnecessary biopsies could be avoided, with only one (1.5%) patient with csPC being missed.
conclusionsPHI is more available for detecting csPC than PSA and PSA F/T. Moreover, there is a possibility that unnecessary prostate biopsies can be avoided by combining PHI and PI-RADS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.